SCHEMBL25370268

SCHEMBL25370268

C=CC(=O)Nc1cc2c(Nc3ccnc(-c4ccccc4F)c3)ncnc2cc1N1CCN(C)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 20/20 0.68
▸ ERBB2 P04626 4/20 0.51
▸ STK10 O94804 2/20 0.51
▸ YES1 P07947 2/20 0.51
▸ TEC P42680 2/20 0.51
▸ BTK Q06187 2/20 0.51
▸ SLK Q9H2G2 2/20 0.51
▸ MAP3K1 Q13233 1/20 0.51
▸ KDR P35968 3/20 0.47
▸ ERBB3 P21860 3/20 0.47
▸ DUS2 Q9NX74 1/20 0.47
▸ IGF1R P08069 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ KIT P10721 2/20 0.46
▸ SRC P12931 2/20 0.46
▸ ERBB4 Q15303 2/20 0.46
▸ BMPR1B O00238 1/20 0.46
▸ CIT O14578 1/20 0.46
▸ MAP2K7 O14733 1/20 0.46
▸ GAK O14976 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25267828 0.93 EGFR (0.59) EGFRERBB2STK10YES1TEC
SCHEMBL25216766 0.91 EGFR (0.56) EGFRERBB2STK10YES1TEC
SCHEMBL25371100 0.90 EGFR (0.55) EGFRERBB2STK10YES1TEC
SCHEMBL30430009 0.90 EGFR (0.54) EGFRERBB2STK10YES1TEC
SCHEMBL25247218 0.90 EGFR (0.54) EGFRERBB2STK10YES1TEC
SCHEMBL25212428 0.87 EGFR (0.72) EGFRERBB2STK10YES1TEC
SCHEMBL25213722 0.86 EGFR (0.51) EGFRERBB2STK10YES1TEC
SCHEMBL25662643 0.86 EGFR (0.51) EGFRERBB2STK10YES1TEC
SCHEMBL25258592 0.86 EGFR (0.53) EGFRERBB2KDRERBB3DUS2
SCHEMBL25217365 0.83 EGFR (0.58) EGFRKDRERBB3DUS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-08-31 — — US disclosed
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-08-31 — — US disclosed
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-08-31 — — US disclosed
EP-4194443-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-06-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF EGFR, WEE1, WEE2 EGFR 1/4885ERBB2 5/4885STK10 2573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback